Your browser doesn't support javascript.
loading
Mesenchymal Stromal Cells from Perinatal Tissues as an Alternative for Ex Vivo Expansion of Hematopoietic Progenitor and Stem Cells from Umbilical Cord Blood.
Bonilla, Ximena; Lara, Ana Milena; Llano-León, Manuela; López-González, David A; Hernández-Mejía, David G; Bustos, Rosa Helena; Camacho-Rodríguez, Bernardo; Perdomo-Arciniegas, Ana-María.
Afiliação
  • Bonilla X; Pharmaceutical Biotechnology Unit, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, Bogotá 111611, Colombia.
  • Lara AM; Pharmaceutical Biotechnology Unit, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, Bogotá 111611, Colombia.
  • Llano-León M; Advanced Therapies Unit, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, Bogotá 111611, Colombia.
  • López-González DA; Pharmaceutical Biotechnology Unit, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, Bogotá 111611, Colombia.
  • Hernández-Mejía DG; Advanced Therapies Unit, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, Bogotá 111611, Colombia.
  • Bustos RH; Therapeutic Evidence Group, Clinical Pharmacology, Universidad de La Sabana and Clínica Universidad de La Sabana, Chía 140013, Colombia.
  • Camacho-Rodríguez B; Pharmaceutical Biotechnology Unit, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, Bogotá 111611, Colombia.
  • Perdomo-Arciniegas AM; Cord Blood Bank, Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud, Bogotá 111611, Colombia.
Int J Mol Sci ; 24(21)2023 Oct 24.
Article em En | MEDLINE | ID: mdl-37958529
Umbilical cord blood (UCB) serves as a source of hematopoietic stem and progenitor cells (HSPCs) utilized in the regeneration of hematopoietic and immune systems, forming a crucial part of the treatment for various benign and malignant hematological diseases. UCB has been utilized as an alternative HSPC source to bone marrow (BM). Although the use of UCB has extended transplantation access to many individuals, it still encounters significant challenges in selecting a histocompatible UCB unit with an adequate cell dose for a substantial proportion of adults with malignant hematological diseases. Consequently, recent research has focused on developing ex vivo expansion strategies for UCB HSPCs. Our results demonstrate that co-cultures with the investigated mesenchymal stromal cells (MSCs) enable a 10- to 15-fold increase in the cellular dose of UCB HSPCs while partially regulating the proliferation capacity when compared to HSPCs expanded with early acting cytokines. Furthermore, the secretory profile of UCB-derived MSCs closely resembles that of BM-derived MSCs. Moreover, both co-cultures exhibit alterations in cytokine secretion, which could potentially impact HSPC proliferation during the expansion process. This study underscores the fact that UCB-derived MSCs possess a remarkably similar supportive capacity to BM-derived MSCs, implying their potential use as feeder layers in the ex vivo expansion process of HSPCs.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Células-Tronco Mesenquimais / Doenças Hematológicas Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Células-Tronco Mesenquimais / Doenças Hematológicas Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Colômbia País de publicação: Suíça